Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010388 | 1.00 | KCNA3 (0.41) | KCNA3MEN1KMT2ADUSP3PTPN5 | |
| SCHEMBL23217835 | 0.93 | CFD (0.39) | KCNA3MEN1KMT2ADUSP3PTPN5 | |
| SCHEMBL30010173 | 0.93 | CFD (0.39) | KCNA3MEN1KMT2ADUSP3PTPN5 | |
| SCHEMBL23217640 | 0.90 | CFD (0.38) | MEN1KMT2ADUSP3PTPN5PTPN11 | |
| SCHEMBL23217511 | 0.90 | DUSP3 (0.42) | MEN1KMT2ADUSP3PTPN5PTPN11 | |
| SCHEMBL30010464 | 0.90 | CFD (0.38) | MEN1KMT2ADUSP3PTPN5PTPN11 | |
| SCHEMBL21437621 | 0.89 | DUSP3 (0.43) | MEN1KMT2ADUSP3PTPN5PTPN11 | |
| SCHEMBL30010285 | 0.88 | DUSP3 (0.41) | MEN1KMT2ADUSP3PTPN5PTPN11 | |
| SCHEMBL23217527 | 0.88 | DUSP3 (0.41) | MEN1KMT2ADUSP3PTPN5PTPN11 | |
| SCHEMBL21438554 | 0.87 | TBXAS1 (0.40) | MEN1KMT2ADUSP3PTPN5PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | KCNA3 4001/4885MEN1 659/4885KMT2A 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.